Adopting weight-based dosing would lower the percentage of MICs and LICs needing to allocate more than 1% of the projected total pharmaceutical expenditure for treating advanced NSCLC with PD1/PD-L1 inhibitor monotherapies to around 13% (Fig. 3b). The gene discussed is CD274; the disease is non-small cell lung carcinoma.